@article{08d7e353e82e4f3d93e9908a146b32d5,
title = "The roles of proteases in prostate cancer",
abstract = "Since the proposition of the pro-invasive activity of proteolytic enzymes over 70 years ago, several roles for proteases in cancer progression have been established. About half of the 473 active human proteases are expressed in the prostate and many of the most well-characterized members of this enzyme family are regulated by androgens, hormones essential for development of prostate cancer. Most notably, several kallikrein-related peptidases, including KLK3 (prostate-specific antigen, PSA), the most well-known prostate cancer marker, and type II transmembrane serine proteases, such as TMPRSS2 and matriptase, have been extensively studied and found to promote prostate cancer progression. Recent findings also suggest a critical role for proteases in the development of advanced and aggressive castration-resistant prostate cancer (CRPC). Perhaps the most intriguing evidence for this role comes from studies showing that the protease-activated transmembrane proteins, Notch and CDCP1, are associated with the development of CRPC. Here, we review the roles of proteases in prostate cancer, with a special focus on their regulation by androgens.",
keywords = "AR, CDCP1, CUB domain-containing protein 1, FAP, KLK, MMP, Notch, PAR, TMPRSS2, androgen, androgen receptor, fibroblast activation protein, hepsin, kallikrein-related peptidases, matriptase, matrix metalloproteinase, peptidases, prostate cancer, protease-activated receptor, proteases, trypsin, uPA, urokinase-type plasminogen activator",
author = "Hannu Koistinen and Kovanen, {Ruusu Maaria} and Hollenberg, {Morley D.} and Antoine Dufour and Radisky, {Evette S.} and Stenman, {Ulf H{\aa}kan} and Jyotsna Batra and Judith Clements and Hooper, {John D.} and Eleftherios Diamandis and Oliver Schilling and Antti Rannikko and Tuomas Mirtti",
note = "Funding Information: The authors wish to acknowledge the support for their protease‐related research from Sigrid Jus{\'e}lius Foundation (HK), Magnus Ehrnrooth foundation (HK), Finnish Society of Clinical Chemistry (HK), Laboratoriol{\"a}{\"a}ketieteen edist{\"a}miss{\"a}{\"a}ti{\"o} (HK), the Academy of Finland (TM) and State funding for university level health research (TM). ESR acknowledges support from US National Institutes of Health grants R01 GM132100, R01GM144393, and R01 CA258274. MDH acknowledges support for protease‐related research from the Canadian Institutes of Health Research (CIHR), Prostate Cancer Canada and the Cancer Fight Foundation‐Calgary Motorcycle Ride for Dad. JB is supported by Advance Queensland Industry Research Fellowship. JDH acknowledges support from the National Health and Medical Research Council (APP1121970) and the Medical Research Future Fund (MRF1199422). OS acknowledges funding by the Deutsche Forschungsgemeinschaft (DFG, projects 446058856, 466359513, 444936968, 405351425, 431336276, 431984000 (SFB 1453 “Nephrogenetics”), 441891347 (SFB 1479 “OncoEscape”), 423813989 (GRK 2606 “ProtPath”), 322977937 (GRK 2344 “MeInBio”)), the ERA PerMed programme (BMBF, 01KU1916, 01KU1915A), and the German Consortium for Translational Cancer Research (project Impro‐Rec). Funding Information: Advance Queensland Industry Research; Calgary Motorcycle Ride for Dad; Canadian Institutes of Health Research; Deutsche Forschungsgemeinschaft, Grant/Award Numbers: 322977937 (GRK 2344 “MeInBio”), 405351425, 423813989 (GRK 2606 “ProtPath”), 431336276, 431984000 (SFB 1453 “Nephrogenetics”), 441891347 (SFB 1479 “OncoEscape”), 444936968, 446058856, 466359513; ERA PerMed, Grant/Award Numbers: 01KU1915A, 01KU1916, BMBF; German Consortium for Translational Cancer Research; Helsingin ja Uudenmaan Sairaanhoitopiiri; Laboratoriol{\"a}{\"a}ketieteen edist{\"a}miss{\"a}{\"a}ti{\"o}; Magnus Ehrnroothin S{\"a}{\"a}ti{\"o}; Medical Research Future Fund, Grant/Award Number: MRF1199422; National Health and Medical Research Council, Grant/Award Number: APP1121970; National Institutes of Health, Grant/Award Numbers: R01 CA258274, R01 GM132100, R01GM144393; Prostate Cancer Canada; Prostate Cancer Fight Foundation; Sigrid Jus{\'e}liuksen S{\"a}{\"a}ti{\"o}; Suomen Akatemia; Suomen kliinisen kemian yhdistys Funding information Funding Information: The authors wish to acknowledge the support for their protease-related research from Sigrid Jus{\'e}lius Foundation (HK), Magnus Ehrnrooth foundation (HK), Finnish Society of Clinical Chemistry (HK), Laboratoriol{\"a}{\"a}ketieteen edist{\"a}miss{\"a}{\"a}ti{\"o} (HK), the Academy of Finland (TM) and State funding for university level health research (TM). ESR acknowledges support from US National Institutes of Health grants R01 GM132100, R01GM144393, and R01 CA258274. MDH acknowledges support for protease-related research from the Canadian Institutes of Health Research (CIHR), Prostate Cancer Canada and the Cancer Fight Foundation-Calgary Motorcycle Ride for Dad. JB is supported by Advance Queensland Industry Research Fellowship. JDH acknowledges support from the National Health and Medical Research Council (APP1121970) and the Medical Research Future Fund (MRF1199422). OS acknowledges funding by the Deutsche Forschungsgemeinschaft (DFG, projects 446058856, 466359513, 444936968, 405351425, 431336276, 431984000 (SFB 1453 “Nephrogenetics”), 441891347 (SFB 1479 “OncoEscape”), 423813989 (GRK 2606 “ProtPath”), 322977937 (GRK 2344 “MeInBio”)), the ERA PerMed programme (BMBF, 01KU1916, 01KU1915A), and the German Consortium for Translational Cancer Research (project Impro-Rec). Publisher Copyright: {\textcopyright} 2022 The Authors. IUBMB Life published by Wiley Periodicals LLC on behalf of International Union of Biochemistry and Molecular Biology.",
year = "2023",
month = jun,
doi = "10.1002/iub.2700",
language = "English (US)",
volume = "75",
pages = "493--513",
journal = "IUBMB Life",
issn = "1521-6543",
publisher = "Wiley-Blackwell",
number = "6",
}